These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23242248)

  • 1. Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy.
    Oike T; Ohno T; Noda SE; Sato H; Tamaki T; Kiyohara H; Ando K; Nakano T
    J Radiat Res; 2013 May; 54(3):474-8. PubMed ID: 23242248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
    Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
    Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
    Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
    Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
    Rose BS; Liang Y; Lau SK; Jensen LG; Yashar CM; Hoh CK; Mell LK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1185-91. PubMed ID: 22270171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovator and generic cisplatin formulations: comparison of renal toxicity.
    Sekine I; Kubota K; Tamura Y; Asahina H; Yamada K; Horinouchi H; Nokihara H; Yamamoto N; Tamura T
    Cancer Sci; 2011 Jan; 102(1):162-5. PubMed ID: 21054679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
    Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
    Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: comparison with radiation therapy alone.
    Ohno T; Kato S; Wakatsuki M; Noda SE; Murakami C; Nakamura M; Tsujii H
    Gynecol Oncol; 2006 Oct; 103(1):94-9. PubMed ID: 16527337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
    Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
    Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.
    Erpolat OP; Alco G; Caglar HB; Igdem S; Saran A; Dagoglu N; Aslay I; Ozsaran Z; Demirci S; Keven E; Guney Y; Akmansu M; Kilic D; Bayman E; Etiz D; Mandel NM
    Eur J Gynaecol Oncol; 2014; 35(1):62-6. PubMed ID: 24654465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix.
    Uno T; Mitsuhashi A; Isobe K; Yamamoto S; Kawakami H; Ueno N; Usui H; Tate S; Kawata T; Ito H
    Int J Gynecol Cancer; 2008; 18(1):80-4. PubMed ID: 17466053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome.
    Vandecasteele K; Makar A; Van den Broecke R; Delrue L; Denys H; Lambein K; Lambert B; van Eijkeren M; Tummers P; De Meerleer G
    Strahlenther Onkol; 2012 Jul; 188(7):576-81. PubMed ID: 22526231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-field intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy for postoperative cervical cancer with common iliac or para-aortic lymph node metastases: a retrospective review in a single institution.
    Zhang G; Fu C; Zhang Y; Wang J; Qiao N; Yang Q; Cheng Y
    Int J Gynecol Cancer; 2012 Sep; 22(7):1220-5. PubMed ID: 22854654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity of concurrent chemoradiotherapy for locally advanced cervical cancer.
    Jakubowicz J; Blecharz P; Skotnicki P; Reinfuss M; Walasek T; Luczynska E
    Eur J Gynaecol Oncol; 2014; 35(4):393-9. PubMed ID: 25118480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
    Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
    Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
    Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: An observational study of 10-year experience.
    Lee J; Lin JB; Sun FJ; Chen YJ; Chang CL; Jan YT; Wu MH
    Medicine (Baltimore); 2017 Mar; 96(10):e6158. PubMed ID: 28272204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.
    Simpson DR; Song WY; Moiseenko V; Rose BS; Yashar CM; Mundt AJ; Mell LK
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e81-6. PubMed ID: 22516388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Effects of Hemoglobin Levels Upon Tumor Response among Cervical Carcinoma Patients Undergoing Accelerated Hyperfractionated Radiotherapy versus Cisplatin Chemoradiotherapy.
    Thakur P; Seam RK; Gupta MK; Rastogi M; Gupta M; Bhattacharyya T; Sharma M; Revannasiddaiah S
    Asian Pac J Cancer Prev; 2015; 16(10):4285-9. PubMed ID: 26028087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.